0J9P.LSE Incyte Corp.

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
29.0x
P/B
-
ROE
2.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0J9P.LSE undervalued?

Graham number

The Graham number of Incyte Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Incyte Corp. fundamental analysis

No fundamental analysis for Incyte Corp. yet.

Incyte Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Incyte Corp.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment…

Full company profile